Glaukos Corporation (NYSE:GKOS) has received a consensus recommendation of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $48.80.

A number of equities analysts recently commented on the company. BMO Capital Markets reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Glaukos Corporation in a research note on Wednesday. Zacks Investment Research lowered Glaukos Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, September 20th. BidaskClub lowered Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Stephens reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Glaukos Corporation in a research note on Friday, September 15th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Glaukos Corporation in a research note on Friday, September 15th.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/18/glaukos-corporation-gkos-given-consensus-rating-of-buy-by-brokerages-2.html.

Glaukos Corporation (GKOS) traded up 3.13% on Wednesday, reaching $33.62. 336,753 shares of the company’s stock were exchanged. Glaukos Corporation has a 52 week low of $28.72 and a 52 week high of $52.49. The company’s market cap is $1.16 billion. The stock’s 50 day moving average is $33.87 and its 200 day moving average is $33.87.

In other news, CEO Thomas William Burns sold 73,788 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $41.36, for a total transaction of $3,051,871.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc sold 325,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $37.93, for a total value of $12,327,250.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 980,200 shares of company stock valued at $37,900,263. 16.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new stake in shares of Glaukos Corporation during the second quarter valued at approximately $129,356,000. Capital World Investors increased its holdings in shares of Glaukos Corporation by 17.1% during the second quarter. Capital World Investors now owns 2,740,000 shares of the medical instruments supplier’s stock valued at $113,628,000 after acquiring an additional 400,000 shares in the last quarter. William Blair Investment Management LLC increased its holdings in shares of Glaukos Corporation by 4.9% during the second quarter. William Blair Investment Management LLC now owns 2,164,764 shares of the medical instruments supplier’s stock valued at $89,773,000 after acquiring an additional 100,320 shares in the last quarter. Janus Capital Management LLC increased its holdings in shares of Glaukos Corporation by 88.5% during the first quarter. Janus Capital Management LLC now owns 1,765,069 shares of the medical instruments supplier’s stock valued at $90,545,000 after acquiring an additional 828,567 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Glaukos Corporation by 3.4% during the second quarter. Vanguard Group Inc. now owns 1,668,345 shares of the medical instruments supplier’s stock valued at $69,187,000 after acquiring an additional 55,507 shares in the last quarter. Hedge funds and other institutional investors own 88.95% of the company’s stock.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.